REGENXBIO Inc. (NASDAQ:RGNX) Shares Bought by BNP Paribas Financial Markets

BNP Paribas Financial Markets lifted its position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 370.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 96,093 shares of the biotechnology company's stock after purchasing an additional 75,652 shares during the period. BNP Paribas Financial Markets owned 0.19% of REGENXBIO worth $743,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in RGNX. Ameriprise Financial Inc. boosted its position in shares of REGENXBIO by 4.7% in the fourth quarter. Ameriprise Financial Inc. now owns 284,521 shares of the biotechnology company's stock valued at $2,199,000 after acquiring an additional 12,883 shares during the period. Jane Street Group LLC boosted its position in shares of REGENXBIO by 325.3% in the fourth quarter. Jane Street Group LLC now owns 164,911 shares of the biotechnology company's stock valued at $1,275,000 after acquiring an additional 126,135 shares during the period. PDT Partners LLC bought a new stake in shares of REGENXBIO in the fourth quarter valued at about $487,000. Voya Investment Management LLC boosted its position in shares of REGENXBIO by 7.5% in the fourth quarter. Voya Investment Management LLC now owns 43,502 shares of the biotechnology company's stock valued at $336,000 after acquiring an additional 3,024 shares during the period. Finally, Adage Capital Partners GP L.L.C. bought a new stake in shares of REGENXBIO in the fourth quarter valued at about $3,865,000. Institutional investors own 88.08% of the company's stock.

Insider Activity at REGENXBIO

In other news, Director Kenneth T. Mills sold 20,602 shares of the firm's stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $7.91, for a total value of $162,961.82. Following the completion of the transaction, the director now directly owns 475,103 shares in the company, valued at $3,758,064.73. This trade represents a 4.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 12.79% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Wall Street Zen raised REGENXBIO from a "sell" rating to a "hold" rating in a research note on Friday, March 7th. HC Wainwright dropped their price target on REGENXBIO from $36.00 to $34.00 and set a "buy" rating for the company in a research note on Monday, March 17th. The Goldman Sachs Group dropped their price target on REGENXBIO from $14.00 to $12.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. Leerink Partners set a $24.00 price target on REGENXBIO in a research note on Tuesday, March 18th. Finally, Raymond James assumed coverage on REGENXBIO in a research note on Friday, February 7th. They issued an "outperform" rating and a $27.00 price target for the company. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, REGENXBIO presently has an average rating of "Moderate Buy" and an average target price of $31.63.

REGENXBIO Stock Down 3.9%

Shares of NASDAQ RGNX traded down $0.36 during trading on Wednesday, reaching $8.71. The company had a trading volume of 52,038 shares, compared to its average volume of 883,000. REGENXBIO Inc. has a 12-month low of $5.04 and a 12-month high of $15.39. The stock has a market cap of $437.04 million, a PE ratio of -1.74 and a beta of 1.11. The business's 50-day moving average is $7.86 and its 200 day moving average is $7.98.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.41 by ($0.29). REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. The company had revenue of $89.01 million during the quarter, compared to the consensus estimate of $105.35 million. On average, analysts anticipate that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.